Ovid Therapeutics Stock: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally
· seekingalpha.com
Ovid (OVID) Buy thesis: undervalued despite 700% surge, $193M cash runway to 2029, epilepsy & schizophrenia pipeline catalysts. See more here.
In June 2024, Takeda, a company to which Ovid Therapeutics ( OVID ) out-licensed one of their epilepsy drugs, announced that it narrowly missed its primary endp...